Details emerge in link between body mass...
MD Anderson researchers discussed new data on the connection between body mass index (BMI) and response to presurgical chemotherapy in patients with inflammatory breast cancer during a poster discussion at the 36th annual CTRC-AACR San Antonio Breast Cancer Symposium.
The study examined 1,002 cases of patients with inflammatory breast cancer or locally advanced non-inflammatory breast cancer between 2006-2012. It was the first...
Drug combo helps 95% of CLL clinical trial patients; ibrutinib...
Even as the targeted therapy ibrutinib makes its way through clinical trials as a single treatment for chronic lymphocytic leukemia...
Super gene MUC5B provides mucus required for strong airway defense
In a typical day, each of us swallows 30 milliliters of mucus from our lungs. A mucus blanket is swept from the most distant airways...
Researchers call on Sleeping Beauty to...
When it comes to equipping T cells, the immune system's attack dogs, to find and kill cancer cells, Sleeping Beauty just might be a heroine in the story.
Genetically altering T cells to recognize a surface protein called CD19 and destroy cells that wear it has shown great promise for treating blood cancers, most recently in clinical trials presented during this week at the 55th American Society of Hematology (ASH) Annual Meeting...
New targeted therapy halts CLL for more than 2 years and counting
Patients on an extended clinical trial of the targeted therapy ibrutinib have their relapsed or resistant chronic lymphocytic leukemia...
Institutions team up to form 'collective brain' to defeat lethal...
Glioblastoma multiforme, the most common and lethal form of brain cancer, "is one of the science and medical world's hardest nuts to...
FDA lymphoma drug approval based on MD Anderson-led clinical trial
The U.S. Food and Drug Administration today approved ibrutinib for treatment of patients with mantle cell lymphoma who have received...
Advanced form of proton therapy offers benefits for head, neck...
Oral cancer patients with tumors at the back of the throat are half as likely to require a feeding tube when treated with intensity...
Eating and swallowing exercises during treatment benefit cancer...
New MD Anderson research published in JAMA Otolaryngology Head and Neck Surgery indicates that oral exercises help patients maintain...
Head and neck cancer patients have varied risks for second...
MD Anderson-led research published in the journal Cancer is shedding light on the risk of second primary malignancies, a leading cause...
Joining a clinical trial to prevent breast cancer recurrence
I finished the most active treatment phase for male breast cancer in the first week of June, enjoyed a few weeks off...
Brain tumor thrives when its immature cells are safe from growing...
In glioblastoma multiforme (GBM), the most common and lethal brain tumor, lack of differentiation makes a big, and bad...
First targeted drug may end cancer-promoting Skp2's days of...
A protein called Skp2, overexpressed in many types of cancer, for years has gotten away with promoting tumor growth and progression...
Triple-negative breast cancer thrives by producing its own growth...
Triple-negative breast cancer cells produce inflammatory cytokines Interleukin-6 (IL-6) and Interleukin-8 (IL-8), which in turn...
Research uncovers tie between two cancer-promoters in breast cancer
MD Anderson scientists have found a molecular signaling pathway that connects two known contributors to cancer cell growth and...
Protein biomarker may signify aggressive colon cancer
MET protein levels correlate strongly with a cellular transition that occurs in a treatment-resistant type of colorectal cancer,...
Brain cancer: Cognition and quality of life important factors
In a large national, cooperative trial led by MD Anderson, researchers determined bevacizumab (Avastin), did not offer survival...
Drug doesn't extend survival for newly diagnosed glioblastoma...
Following surgery, radiation and chemotherapy with a drug that hinders formation of tumor-supporting blood vessels does...
Immunotherapy researcher inspiring hope beyond the lab
Why is our immune system usually not capable of eradicating cancerous tumor cells?
This is the main question that Greg Lizee, Ph.D....
Arrested development: Suffocating cancer cells cheat death with...
The epidermal growth factor receptor (EGFR) often goes haywire in cancer, sending constant, urgent signals into a cell, telling it to...
Fast food restaurants contribute to African-Americans tipping the...
The U.S. Centers for Disease Control and Prevention estimates obesity to be a contributing factor to millions of dollars in health...
Key protein fires up central nervous system inflammation
A pivotal protein leads to autoimmune inflammation of the central nervous system in a mouse model of multiple sclerosis (MS) and...
Challenges and opportunities in drug discovery and development
"Cancer is a complex and heterogeneous disease driven by gene mutations. As we enter the era of personalized medicine, the...
MD Anderson cancer research revealed, honored at AACR annual...
MD Anderson scientists Jim Allison and Hagop Kantarjian, at left, and Guillermina Lozano and Gabriel Hortobagyi, at right, won four of...
MD Anderson genetics chair Guillermina Lozano wins AACR lectureship
The first of six awards to scientists at The University of Texas MD Anderson Cancer Center at this year's AACR Annual Meeting 2013...
Study uncovers actin's action in the nucleus, a break in protein's...
Actin is a protein that has been long known to work by linking itself into chains to form filaments. Providing rigidity to the cell,...
New drugs are too slow getting to children with cancer
Recently, the U.S. Food and Drug Administration (FDA) approved the use of Gleevec in combination with chemotherapy to treat newly...
Cancer vaccine ingredient subverts immune attack, diverts it from...
For years, scientists have crafted vaccines designed to treat cancer, rather than to prevent it, by priming the immune system to track...
New approach helps more smokers connect to tobacco treatment
Smoking remains the leading cause of preventable illness and death in the United States, so the health benefits of quitting are...
New initiatives drive personalized cancer care via genetic...
Gordon Mills, M.D., Ph.D., recalls a proposal he wrote 18 years ago detailing the concept of personalized cancer therapy and its...
Drug is first to control recurrent low-grade ovarian cancer
A phase 2 clinical trial of a targeted therapy provides evidence that there might, at last, be a treatment that shrinks or stifles the...
Killer wound-healing; stress and ovarian cancer; blood vessels'...
A key to the perils of endless injury repair, the molecular path from stress through a cancer-promoting gene to ovarian...
Chromatin gets a makeover; review in Cell explains
Chromatin, the intertwined histone proteins and DNA that are packaged into chromosomes, has long been recognized...
Rescuer has TRAF3's back, keeping cancer and autoimmunity at bay
When a crucial enzyme is dotted with targets that summon an attack by a cell's protein-destroying complex, another molecule comes to...
Translating research into better treatment: We can boost our...
By Naoto Ueno M.D., Ph.D.
Each year, on the basis of new basic research discoveries and clinical observations, my research group...
Innovator plans to map genome of single cells to paint cancer's...
Cancer begins when a single cell goes haywire. Now the keys to understanding that cell's transition to lethal tumor may be found in...